News & Updates
Excerpt from the Press Release: ROTTERDAM, Netherlands and SAN DIEGO, March 12, 2025 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology and, inflammatory and infectious diseases, proudly announces the publication of a groundbreaking study titled “Enhanced Risk Stratification for Sentinel Lymph Node Biopsy in Head…
Read More
Excerpt from the Press Release: AUSTIN, Texas & PHILADELPHIA–(BUSINESS WIRE)–Faeth Therapeutics (Faeth), a clinical-stage biotechnology company focused on metabolism, and The GOG Foundation, Inc. (GOG-F), a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies, today announced the first…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, will highlight progress across its clinical pipeline, including continued advancement of…
Read More
In clinical trials, the accuracy, efficiency, and integrity of data collection are paramount. Electronic Data Capture (EDC) vendors play a crucial role in ensuring these standards are met, and two key groups that facilitate this are project managers and technical support teams. Together, they help sponsors navigate the complexities of clinical trials, from initial setup…
Read More
ADS051 is the first and only MRP2 / FPR1 inhibitor to demonstrate favorable safety and tolerability with signals of clinical efficacy with relief from disruptive symptoms of inflammatory bowel disease in a multiple ascending dose (MAD) study of moderately to severely active Ulcerative Colitis (UC) patients in relapse ADS051 was demonstrated to be safe in a single ascending dose (SAD) study in…
Read More
— Study supported FDA and Health Canada approvals of DAYBUE for treatment of Rett syndrome in patients ages two years and older — Results consistent with Phase 3 LAVENDER™ and open-label LILAC™ studies Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the journal Medpublished results from the open-label…
Read More
– Exploratory phase 1b trial will evaluate safety, tolerability and effect on pain intensity– Topline data readout planned for early 2026 Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today…
Read More
Excerpt from the Press Release: SAN DIEGO, March 5, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational compound NBI-1140675 in healthy adult participants. NBI-1140675 is an investigational, oral, selective second-generation small molecule inhibitor of the…
Read More
Excerpt from the Press Release: LEXINGTON, Mass.–(BUSINESS WIRE)– Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy. Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and…
Read More
Poster presented at the 2025 AACR:IO Conference Company’s novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (FHAB®) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor Excerpt from the Press Release: PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) — Sonnet BioTherapeutics Holdings,…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?